NCT02061709View on ClinicalTrials.gov

Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber

PHASE2CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Seasonal Allergic Rhinitis
Interventions
BIOLOGICAL

Ragweed-SPIRE

BIOLOGICAL

Placebo

Trial Locations (5)

K2L 3C8

Kanata Allergy Services, Kanata

N6A 5R8

KGK Synergize Inc, London

L8P 0A1

Inflamax Research, Mississauga

L1H 7K4

Taunton Health Centre, Oshawa

N8X 2G1

Windsor Allergy Asthma Associates, Windsor

Sponsors

Collaborators (1)

Adiga Life Sciences, Inc.
All Listed Sponsors
collaborator

Adiga Life Sciences, Inc.

INDUSTRY

lead

Circassia Limited

INDUSTRY

NCT02061709 - Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber | Biotech Hunter | Biotech Hunter